Enlivex Raises $7.5M at 10.5% Premium With Warrants Attached
ENLV is trading near its 52-week low of $1.18 (8.5% below the low) on light trading volume (0.3× avg).
Summary
Enlivex priced a $7.5M registered direct offering at $1.315 per share, a 10.5% premium to the prior close, with a $1.578 warrant attached. The premium pricing is unusual for a micro-cap raise and suggests demand rather than distress selling. The company is tiny and trading near its 52-week low after a 1-for-16 reverse split took effect October 27; it also received a Nasdaq delisting notice the same day for failing the $1.00 bid price test. This cash buys time, but the attached warrants add dilution on top of an already authorized ATM and shelf capacity. The raise follows a roughly 60% workforce cut announced October 19 and 12-month Phase IIa Allocetra data reported November 2.
At the time of this announcement, ENLV was trading at $1.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8M. The 52-week trading range was $1.18 to $434.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.